MiR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth

Marija Mihailovich, Michael Bremang, Valeria Spadotto, Daniele Musiani, Elena Vitale, Gabriele Varano, Federico Zambelli, Francesco M. Mancuso, David A. Cairns, Giulio Pavesi, Stefano Casola, Tiziana Bonaldi

Research output: Contribution to journalArticlepeer-review


The synergism between c-MYC and miR-17-19b, a truncated version of the miR-17-92 cluster, is well-documented during tumor initiation. However, little is known about miR-17-19b function in established cancers. Here we investigate the role of miR-17-19b in c-MYC-driven lymphomas by integrating SILAC-based quantitative proteomics, transcriptomics and 3′ untranslated region (UTR) analysis upon miR-17-19b overexpression. We identify over one hundred miR-17-19b targets, of which 40% are co-regulated by c-MYC. Downregulation of a new miR-17/20 target, checkpoint kinase 2 (Chek2), increases the recruitment of HuR to c-MYC transcripts, resulting in the inhibition of c-MYC translation and thus interfering with in vivo tumor growth. Hence, in established lymphomas, miR-17-19b fine-tunes c-MYC activity through a tight control of its function and expression, ultimately ensuring cancer cell homeostasis. Our data highlight the plasticity of miRNA function, reflecting changes in the mRNA landscape and 3' UTR shortening at different stages of tumorigenesis.

Original languageEnglish
Article number8725
JournalNature Communications
Publication statusPublished - Nov 10 2015

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'MiR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth'. Together they form a unique fingerprint.

Cite this